WeVote
Log In

Bill

Bill

S 3220

Establishes "Opioid Prevention and Rehabilitation Program Fund" and tax on opioid drugs.

2026-2027 Regular Session Introduced by Shirley Turner

New Jersey proposes taxing opioid drugs to fund dedicated prevention and rehabilitation programs addressing the state's opioid crisis.

0
WeVote Research Nonpartisan
Bill Summary · S 3220

Legislative bill overview

S 3220 creates a dedicated funding mechanism for opioid prevention and treatment programs in New Jersey by establishing a new tax on opioid medications. The revenue generated would be deposited into a specialized "Opioid Prevention and Rehabilitation Program Fund" to support addiction services, recovery programs, and prevention initiatives across the state.

Why is this important

New Jersey has been significantly impacted by the opioid crisis, with thousands of overdose deaths and widespread addiction affecting communities statewide. Dedicated funding streams allow for sustained, comprehensive responses to addiction rather than relying on fragmented or temporary appropriations. This creates a direct fiscal link between the pharmaceutical products contributing to the crisis and resources dedicated to addressing it.

Potential points of contention

  • Industry cost-shifting: Pharmaceutical manufacturers and distributors may argue the tax unfairly targets their sector and could be passed to consumers through higher medication prices, potentially limiting access to legitimate pain management
  • Funding adequacy concerns: Critics may question whether tax revenues will be sufficient to meaningfully address the opioid crisis or whether the fund mechanism guarantees sustained, effective spending
  • Scope of coverage: Debate may arise over which opioids are taxed (prescription vs. all types), whether the tax applies equally to generic and brand drugs, and how exemptions for specific medical uses would be determined

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.